SCHEMBL2994760

SCHEMBL2994760

O=C(CCc1ccccc1)Nc1ccc(Cl)c(NC2=NC(=O)C(=Cc3ccc4ncccc4c3)S2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.46
DYRK3 O43781 2/20 0.42
PLAU P00749 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CDK1 P06493 2/20 0.41
PIK3CD O00329 1/20 0.40
PIM1 P11309 1/20 0.40
CSNK2A2 P19784 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CG P48736 1/20 0.40
CLK1 P49759 1/20 0.40
CLK3 P49761 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
DYRK1A Q13627 1/20 0.40
HASPIN Q8TF76 1/20 0.40
DYRK2 Q92630 1/20 0.40
MYLK2 Q9H1R3 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2994755 1.00 ALOX5 (0.46) ALOX5DYRK3PLAUMEN1KMT2A
Trifluoroacetic Acid SCHEMBL4099206 0.96 ALOX5 (0.43) ALOX5DYRK3PLAUMEN1KMT2A
Trifluoroacetic Acid SCHEMBL4099194 0.96 ALOX5 (0.43) ALOX5DYRK3PLAUMEN1KMT2A
SCHEMBL4946166 0.91 DYRK3 (0.42) DYRK3MEN1KMT2ACDK1PIK3CD
SCHEMBL4947101 0.91 DYRK3 (0.42) DYRK3MEN1KMT2ACDK1PIK3CD
SCHEMBL4942268 0.89 ALDH1A1 (0.43) DYRK3MEN1KMT2ACDK1PIK3CD
SCHEMBL2993651 0.89 TSHR (0.42) ALOX5DYRK3MEN1KMT2ACDK1
SCHEMBL2993647 0.89 TSHR (0.42) ALOX5DYRK3MEN1KMT2ACDK1
SCHEMBL2989471 0.89 DYRK3 (0.47) DYRK3MEN1KMT2ACDK1PIK3CD
SCHEMBL2989478 0.89 DYRK3 (0.47) DYRK3MEN1KMT2ACDK1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US claimed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP claimed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 ALOX5 2869/4885DYRK3 3748/4885PLAU 3223/4885
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 ALOX5 4155/4885DYRK3 1471/4885PLAU 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.